You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,951,985


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,951,985
Title:Compounds and pharmaceutical compositions for the treatment of viral infections
Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
Inventor(s): Surleraux; Dominique (Wauthier-Braine, BE), Dousson; Cyril B. (Canet, FR), Dukhan; David (Saint Gely du Fesc, FR), Pierra; Claire (Montarnaud, FR)
Assignee: Idenix Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:13/610,574
Patent Claims:1. A compound of Formula I: ##STR00056## or a pharmaceutically acceptable salt, solvate, a tautomeric or polymorphic form thereof, wherein Base is heterocyclyl; A is (CH.sub.2).sub.n, cycloalkylene, heterocyclylene or heteroarylene; n is 1 to 3; each X is independently O or S; R.sup.1 is OH, alkoxy, O-acyl or F; R.sup.2 is NH.sub.2, NH(alkyl), N(alkyl).sub.2, O-alkyl, O-aryl, O-aralkyl, S-alkyl, S-aryl or S-aralkyl; R.sup.3 is OR.sup.5, SR.sup.5,NR.sup.6R.sup.7 or an .alpha.- or .beta.-amino acid ester; R.sup.4 is H or acyl; or R.sup.3 and R.sup.4 together form a 6-8 membered heterocyclic ring; R.sup.5 is hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl; R.sup.6 and R.sup.7 are selected as follows: i) R.sup.6 and R.sup.7 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl; or ii) R.sup.6 and R.sup.7 together with the nitrogen atom on which they are substituted form a 3-7 membered heterocyclic or heteroaryl ring; and R.sup.10 and R.sup.11 are each independently hydrogen, alkyl or aryl.

2. The compound of claim 1, wherein each R.sup.10 and R.sup.11 is hydrogen.

3. The compound of claim 1, wherein each X is O.

4. The compound of claim 1, wherein Base is adenine, cytosine, guanine, hypoxanthine, thymine or uridine.

5. The compound of claim 1, wherein Base is selected from one of formulae (i) to (xxvi): ##STR00057## ##STR00058## ##STR00059## ##STR00060## ##STR00061## wherein each R.sup.L is independently hydrogen, alkyl, cycloalkyl, acyl, carbamyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, sulfonate ester, alkyl sulfonyl, aryl sulfonyl, arylalkyl sulfonyl, a lipid, a phospholipid, an amino acid or a carbohydrate; and each R.sup.M and R.sup.N is independently hydrogen or alkyl; or R.sup.L and R.sup.M together with the N atom to which they are attached from heterocyclyl.

6. The compound of claim 1, or a pharmaceutically acceptable salt, a tautomeric or polymorphic form thereof, of the formula: ##STR00062## wherein each X is independently O or S; R.sup.1 is OH, alkoxy, O-acyl or F; R.sup.2 is NH.sub.2, N(alkyl).sub.2, O-alkyl, O-aryl, O-- aralkyl, S-alkyl, S-aryl or S-aralkyl; R.sup.3 is OR.sup.S, SR.sup.5,NR.sup.6R.sup.7 or an .alpha.- or .beta.-amino acid ester; R.sup.4 is H or acyl; or R.sup.3 and R.sup.4 together for a 6-8 membered heterocyclic ring; R.sup.5 is hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl; R.sup.6 and R.sup.7 are selected as follows: i) R.sup.6 and R.sup.7 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl; or ii) R.sup.6 and R.sup.7 together with the nitrogen atom on which they are substituted form a 3-7 membered heterocyclic or heteroaryl ring. each R.sup.M and R.sup.N is independently hydrogen or alkyl; or R.sup.L and R.sup.M together with the N atom to which they are attached from heterocyclyl.

7. The compound of claim 1, or a pharmaceutically acceptable salt, a tautomeric or polymorphic form thereof, of the formula: ##STR00063## wherein A is (CH.sub.2).sub.n; n is 1 to 2; R.sup.2 is NH.sub.2, N(alkyl).sub.2, O-alkyl, O-aryl, O-- aralkyl, S-alkyl, S-aryl or S-aralkyl; R.sup.3 is NR.sup.6R.sup.7 or an .alpha.- or .beta.-amino acid ester; and R.sup.6 and R.sup.7 are selected as follows: i) R.sup.6 and R.sup.7 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl; or ii) R.sup.6 and R.sup.7 together with the nitrogen atom on which they are substituted form a 3-7 membered heterocyclic or heteroaryl ring; and R.sup.L is methyl or ethyl.

8. The compound of claim 1, or a pharmaceutically acceptable salt, a tautomeric or polymorphic form thereof, of the formula Ia: ##STR00064## wherein R.sup.1 is OH, alkoxy, O-acyl or F; R.sup.2 is O-alkyl or O-benzyl; R.sup.8 is hydrogen, alkyl, aryl or aralkyl; R.sup.9 is alkyl or benzyl; and R.sup.L is methyl or ethyl.

9. A compound of claim 8, wherein R.sup.1 is OH or F; and R.sup.8 is hydrogen, alkyl or benzyl.

10. A compound of claim 8, wherein R.sup.8 is methyl, isopropyl, isobutyl or benzyl.

11. A compound of claim 8, wherein R.sup.2 is methoxy, ethoxy or isopropoxy.

12. A compound of claim 11, wherein R.sup.8 is methyl, isopropyl, isobutyl or benzyl.

13. A compound of claim 12, wherein R.sup.8 is isobutyl.

14. A compound of claim 13, wherein R.sup.9 is methyl, ethyl or isopropyl.

15. A compound of claim 1, or a pharmaceutically acceptable salt, a tautomeric or polymorphic form thereof, wherein the compound is selected from the group consisting of: ##STR00065## ##STR00066## ##STR00067## ##STR00068## ##STR00069## ##STR00070## ##STR00071## ##STR00072## ##STR00073## ##STR00074## ##STR00075## ##STR00076## ##STR00077## ##STR00078## ##STR00079##

16. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient, carrier or diluent.

17. The pharmaceutical composition of claim 16, wherein the composition is an oral formulation.

18. A method for the treatment of a host infected with a hepatitis C virus, comprising the administration of an effective treatment amount of a compound or composition of claim 1.

19. The method of claim 18, wherein the host is a human.

20. The method of claim 18, wherein said administration directs a substantial amount of said compound or pharmaceutically acceptable salt or stereoisomer thereof to the liver of said host.

21. The method of claim 18, wherein said compound or composition is administered in combination or alternation with a second anti-viral agent optionally selected from the group consisting of an interferon, a ribavirin, an interleukin, a NS3 protease inhibitor, a cysteine protease inhibitor, a phenanthrenequinone, a thiazolidine derivative, a thiazolidine, a benzanilide, a helicase inhibitor, a polymerase inhibitor, a nucleotide analogue, a gliotoxin, a cerulenin, an antisense phosphorothioate oligodeoxynucleotide, an inhibitor of IRES-dependent translation, and a ribozyme.

22. The method of claim 21, wherein the second agent is selected from the group consisting of pegylated interferon alpha 2a, interferon alphacon-1, natural interferon, albuferon, interferon beta-1a, omega interferon, interferon alpha, interferon gamma, interferon tau, interferon delta and interferon .gamma.-1b.

Details for Patent 8,951,985

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Biogen Inc. AVONEX interferon beta-1a For Injection 103628 05/17/1996 ⤷  Try a Trial 2031-09-12
Biogen Inc. AVONEX interferon beta-1a Injection 103628 05/28/2003 ⤷  Try a Trial 2031-09-12
Biogen Inc. AVONEX interferon beta-1a Injection 103628 02/27/2012 ⤷  Try a Trial 2031-09-12
Emd Serono, Inc. REBIF interferon beta-1a Injection 103780 03/07/2002 ⤷  Try a Trial 2031-09-12
Emd Serono, Inc. REBIF interferon beta-1a Injection 103780 12/17/2004 ⤷  Try a Trial 2031-09-12
Emd Serono, Inc. REBIF interferon beta-1a Injection 103780 12/21/2012 ⤷  Try a Trial 2031-09-12
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.